ALERT: The M&A Class Action Firm Continues Investigating the Merger – FRLN, CSTR, PCTI, RPT
22 nov. 2023 17h11 HE
|
Monteverde & Associates PC
NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Freeline to Present at the Stifel Healthcare Conference
09 nov. 2022 07h00 HE
|
Freeline Therapeutics Holdings plc
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the...
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 oct. 2022 16h01 HE
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory...
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
04 oct. 2022 07h00 HE
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1...
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 sept. 2022 17h30 HE
|
Freeline Therapeutics Holdings plc
LONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory...
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
09 août 2022 07h00 HE
|
Freeline Therapeutics Holdings plc
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued...
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 août 2022 16h01 HE
|
Freeline Therapeutics Holdings plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole...
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
10 juil. 2022 03h00 HE
|
Freeline Therapeutics
FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON, July 10, 2022 (GLOBE NEWSWIRE) -- Freeline...
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 juil. 2022 16h01 HE
|
Freeline Therapeutics
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to...
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
24 juin 2022 09h32 HE
|
Freeline Therapeutics
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene...